Experience with prostate-specific antigen in prostatic carcinoma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A total of 71 prostatic tumour patients and 45 prostatic adenoma patients were tested for prostate-specific antigen (PSA), immunological prostatic acid phosphatase (PAP) concentration as well as serum prostatic phosphatase (SPP) and enzymic serum phosphatase. It was found among untreated patients that PSA showed the highest percentage of pathologic affection in each stage. PSA, on the evidence of clearance test in the initial days of therapy and after a follow-up period of several months, gave a good picture of the course that the disease had taken.

Original languageEnglish
Pages (from-to)465-472
Number of pages8
JournalInternational Urology and Nephrology
Volume23
Issue number5
DOIs
Publication statusPublished - Sep 1991

Fingerprint

Prostate-Specific Antigen
Carcinoma
Phosphoric Monoester Hydrolases
Prostatic Hyperplasia
Serum
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Urology
  • Nephrology
  • Geriatrics and Gerontology

Cite this

Experience with prostate-specific antigen in prostatic carcinoma. / Romics, I.; Bach, D.

In: International Urology and Nephrology, Vol. 23, No. 5, 09.1991, p. 465-472.

Research output: Contribution to journalArticle

@article{d3c7614cc9434551b75c38188d727f2c,
title = "Experience with prostate-specific antigen in prostatic carcinoma",
abstract = "A total of 71 prostatic tumour patients and 45 prostatic adenoma patients were tested for prostate-specific antigen (PSA), immunological prostatic acid phosphatase (PAP) concentration as well as serum prostatic phosphatase (SPP) and enzymic serum phosphatase. It was found among untreated patients that PSA showed the highest percentage of pathologic affection in each stage. PSA, on the evidence of clearance test in the initial days of therapy and after a follow-up period of several months, gave a good picture of the course that the disease had taken.",
author = "I. Romics and D. Bach",
year = "1991",
month = "9",
doi = "10.1007/BF02583990",
language = "English",
volume = "23",
pages = "465--472",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Experience with prostate-specific antigen in prostatic carcinoma

AU - Romics, I.

AU - Bach, D.

PY - 1991/9

Y1 - 1991/9

N2 - A total of 71 prostatic tumour patients and 45 prostatic adenoma patients were tested for prostate-specific antigen (PSA), immunological prostatic acid phosphatase (PAP) concentration as well as serum prostatic phosphatase (SPP) and enzymic serum phosphatase. It was found among untreated patients that PSA showed the highest percentage of pathologic affection in each stage. PSA, on the evidence of clearance test in the initial days of therapy and after a follow-up period of several months, gave a good picture of the course that the disease had taken.

AB - A total of 71 prostatic tumour patients and 45 prostatic adenoma patients were tested for prostate-specific antigen (PSA), immunological prostatic acid phosphatase (PAP) concentration as well as serum prostatic phosphatase (SPP) and enzymic serum phosphatase. It was found among untreated patients that PSA showed the highest percentage of pathologic affection in each stage. PSA, on the evidence of clearance test in the initial days of therapy and after a follow-up period of several months, gave a good picture of the course that the disease had taken.

UR - http://www.scopus.com/inward/record.url?scp=0025881411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025881411&partnerID=8YFLogxK

U2 - 10.1007/BF02583990

DO - 10.1007/BF02583990

M3 - Article

VL - 23

SP - 465

EP - 472

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 5

ER -